AR071036A1 - Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1. - Google Patents

Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1.

Info

Publication number
AR071036A1
AR071036A1 ARP090101036A ARP090101036A AR071036A1 AR 071036 A1 AR071036 A1 AR 071036A1 AR P090101036 A ARP090101036 A AR P090101036A AR P090101036 A ARP090101036 A AR P090101036A AR 071036 A1 AR071036 A1 AR 071036A1
Authority
AR
Argentina
Prior art keywords
treatment
cx3cr1
disustitutes
tiazolo
pirimidin
Prior art date
Application number
ARP090101036A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR071036A1 publication Critical patent/AR071036A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Composiciones farmacéuticas que los contienen y su uso en terapia. Los compuestos de formula (1) son antagonistas del receptor CX3CR1 y son, por lo tanto, particularmente utiles en el tratamiento o profilaxis de trastornos neurodegenerativos, desmielinizacion, trastornos ateroscleroticos cardio y cerebrovasculares, enfermedad de las arterias periféricas, artritis reumatoide, enfermedades pulmonares, tales como EPOC, asma o dolor. Reivindicacion 1: Un compuesto de formula (1) donde: R1 representa CH3 o C2H5; R2 representa H o CH3; R3 representa H o CH3; R4 representa H, CH3 o C2H5; R5 representa H, CH3 o C2H5; R6 representa H, CH3 o C2H5; R7 representa H, CH3 o C2H5; o una de sus sales farmacéuticamente aceptables.
ARP090101036A 2008-03-26 2009-03-23 Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1. AR071036A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3946308P 2008-03-26 2008-03-26

Publications (1)

Publication Number Publication Date
AR071036A1 true AR071036A1 (es) 2010-05-19

Family

ID=41114185

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101036A AR071036A1 (es) 2008-03-26 2009-03-23 Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1.

Country Status (7)

Country Link
US (1) US20090247555A1 (es)
AR (1) AR071036A1 (es)
CL (1) CL2009000750A1 (es)
PE (1) PE20091683A1 (es)
TW (1) TW200944533A (es)
UY (1) UY31734A (es)
WO (1) WO2009120140A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2648754A4 (en) 2010-12-07 2016-02-24 Philadelphia Health & Educatio METHODS OF INHIBITING THE METASTASIS OF CANCER
JO3082B1 (ar) 2011-09-13 2017-03-15 Eisai R&D Man Co Ltd مشتق بيروليدين-3- يل حمض خليك
US8476301B2 (en) 2011-09-13 2013-07-02 Eisai R&D Management Co., Ltd. Pyrrolidin-3-ylacetic acid derivative
US9550732B2 (en) 2013-03-12 2017-01-24 Eisai R&D Management Co., Ltd. Salt of pyrrolidin-3-yl acetic acid derivative and crystals thereof
US11267817B2 (en) 2017-05-02 2022-03-08 Drexel University Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds
WO2024083933A1 (en) 2022-10-19 2024-04-25 Astrazeneca Ab 2,4,6-trisubstituted 1,3,5-triazines as modulators of cx 3cr1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
SE0101322D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221828D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
AR053347A1 (es) * 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
TW200820973A (en) * 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480

Also Published As

Publication number Publication date
WO2009120140A1 (en) 2009-10-01
UY31734A (es) 2009-11-10
TW200944533A (en) 2009-11-01
PE20091683A1 (es) 2009-12-04
CL2009000750A1 (es) 2010-10-15
US20090247555A1 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
UY29451A1 (es) Derivados novedosos de (1,3)tiazolo(4,5-d)pirimidin-2-(3h)-ona 5,7-disustituida
AR071036A1 (es) Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1.
AR055890A1 (es) Derivados de 7-amino-[1,3] tiazolo [4, 5-d] pirimidina 5-sustituida; su preparacion y composicion farmaceutica
CO6321265A2 (es) Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso
CL2012000981A1 (es) Compuestos derivados de 5-etinil-2-[(3-fenil-1h-pirazolo[3.4-d]pirimidin-1-il)metil]quinazolin-4(3h)-ona, inhibidores de fosfoinositida 3-quinasa compuestos intermediarios; sin accion farmacologica; composicion farmaceutica; utiles en el tratamiento de epoc, asma fibrosis quistica y pulmonar, sarcoidosis, entre otras.
ECSP088114A (es) Nuevos derivados de la 2-azetidinona y su uso como inhibidores de absorción del colesterol para el tratamiento de hiperlipidemia
CR10614A (es) Derivados heterociclicos fusionados y metodos de uso
CO6501188A2 (es) Moduladores de piranil aril metil benzoquinazolina alostéricos positivos del receptos m1
CR10682A (es) Compuestos de tiazol pirazolopirimidina
HN2012001265A (es) Modulares alostericos positivos de receptores mi1 de la quinolina amida
CO6382124A2 (es) Antagonistas del receptor ccr2 y usos de los mismos
CR20130339A (es) Nuevos derivados heterocíclicos y su uso en el tratamiento de desordenes neurológicos
UY29503A1 (es) Derivados de amida sustituida y metodos de uso
CL2016002348A1 (es) Agonistas del receptor muscarínico
ATE440834T1 (de) Substituierte arylaminderivate und verwendungsverfahren
ECSP077424A (es) Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3
CO6470866A2 (es) Enantiómeros de compuestos de espirooxindol y sus usos como agentes terapéuticos.
DOP2011000135A (es) Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1
UY32629A (es) Compuestos antivirales, composiciones y uso para la manufactura de un medicamento para el tratamiento de trastornos asociados con hepatitis c.
AR075729A1 (es) Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes.
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
ECSP078052A (es) Nuevos derivados de la 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones hiperlipidémicas
UY32574A (es) Antagonistas del receptor cxcr3
CL2007003191A1 (es) Compuestos derivados de pirimido-piridona, inhibidores de las proteina quinasas; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como artritis, sindrome de colon irritable, sindrome disneico agudo del adulto, epoc y para el
ECSP078051A (es) Nuevos derivados de la 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones hiperlipidémicas

Legal Events

Date Code Title Description
FB Suspension of granting procedure